Full-Time

Senior Pharmacovigilance System Architect

MMS

MMS

1,001-5,000 employees

Regulatory compliance and data solutions provider

No salary listed

United States

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
ISO 9001
Database Administration

Get referred to MMS

See people who can refer or advise you

Requirements
  • A college degree in an Information Technology discipline or related field, or relevant experience.
  • At least 5 years of experience in Information Technology or a similar field.
  • Expert knowledge of scientific principles and concepts.
  • A reputation as an emerging leader in the field with sustained performance and accomplishment.
  • Proficiency with Microsoft Office applications.
  • Good communication skills and willingness to work with others to clearly understand needs and solve problems.
  • Excellent problem-solving skills.
  • Good organizational and communication skills.
  • Familiarity with 21 CFR Part 11, FDA, and Good Clinical Practice requirements.
  • Basic understanding of contract research organizations, scientific and clinical data and terminology, and the drug development process.
Responsibilities
  • Serve as Database Administrator for Argus Safety, including database configuration, issue resolution, maintenance, governance, and daily support.
  • Perform installations, upgrades, configuration of reporting rules, and E2B reporting via gateway technologies, including setup and configuration of Axway Gateway Interchange.
  • Provide support for all systems associated with pharmacovigilance and drug safety.
  • Update Argus configuration and processes according to changing EudraVigilance regulations.
  • Provide support and execute activities related to EudraVigilance testing for various clients.
  • Perform case migration and database transfers, file importing, and other case processing activities.
  • Provide leadership in executing Argus upgrades and related activities.
  • Provide administrator support for other safety databases, such as ARISg.
  • Perform periodic coding dictionary updates for Argus using MedDRA and WHO Drug.
  • Provide technical assistance and support to the Drug Safety Associate team with electronic submissions of serious adverse events to European agencies.
  • Write procedural documents, including Standard Operating Procedures, Work Practice Documents, and Data Entry Manuals, for Argus Safety.
  • Generate case processing metrics, review them, make suggestions, and support process improvement implementation.
  • Maintain technical expertise in regulatory requirements and ensure alignment with company working practices.
  • Assist with business development and capabilities efforts as needed.
  • Interact directly and independently with clients to coordinate all facets of projects and support client capabilities as a pharmacovigilance and drug safety systems subject matter expert.
  • Work with Argus configuration and study setup.
  • Work with global case processing and serious adverse event reporting.
  • Work with global clinical trial development and data.
Desired Qualifications
  • Hands-on experience with clinical trial and pharmaceutical development.
  • Familiarity with current ISO 9001 and ISO 27001 standards.

MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Canton, Ohio

Founded

2006

Get referred to MMS

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Datacise reached ACDM finalist status in January 2026, validating MMS's software strategy.
  • West Coast expansion before BIO 2026 targets venture-backed biotechs and faster sponsor acquisition.
  • I-ACT and pediatric-trials partnerships broaden MMS's therapeutic footprint and referral network.

What critics are saying

  • MMS still depends on sponsor-funded biotech budgets; trial delays hit revenue fast in 2026.
  • Private-equity ownership under Lindsay Goldberg pushes margin discipline before culture and retention.
  • Ascendancy in biometrics invites competition from IQVIA, Parexel, and Medidata on bigger accounts.

What makes MMS unique

  • Exploristics acquisition added KerusCloud and deep biostatistics, strengthening MMS's data science edge.
  • Ben Dudley became President in May 2026, sharpening global commercial and scientific execution.
  • Former FDA leaders Somya Dunn and other advisors deepen MMS's regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

20%
MMS Holdings
Feb 12th, 2025
MMS Acquires Exploristics for Data Science Expansion

MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.

TipRanks
Jan 29th, 2024
Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC

On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.

MMS Holdings
Apr 18th, 2023
MMS Named Great Place To Work In The UK

MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”

Applied Clinical Trials
Apr 14th, 2023
People and Business News – 4/23

EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.

Business Wire
Mar 21st, 2023
MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise | Business Wire

MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.